FrancophonIA/ELRC3.0 huggingface dataset:
English: Synflorix was as effective as the comparator in triggering the production of antibodies against five of the polysaccharides that the two vaccines shared in common (4, 9V, 14, 18C and 19F), but it was less effective than the comparator for two (6B and 23F).
Maltese: Synflorix kien effettiv daqs il-vaċċin komparatur fl-istimulazzjoni tal-produzzjoni ta' antikorpi kontra ħamsa mill-polisakkaridi li kien hemm komuni bejn iż-żewġ vaċċini (4, 9V, 14, 18C u 19F), iżda kien inqas effettiv mill-vaċċin komparatur għal tnejn minnhom (6B u 23F).
English: Why is Synflorix approved?
Maltese: Għal xiex ġie approvat Synflorix?
English: Synflorix was effective in protecting against invasive disease: no cases were seen among the 10,000 children given three doses of Synflorix and a booster dose, one case occurred among the 10,000 children given two doses of Synflorix and a booster dose and 12 cases occurred in 10,000 children given the comparator vaccine.
Maltese: Synflorix kien effettiv biex jipproteġi kontra l-marda invażiva: ma ntwera l-ebda każ fost l-10,000 tifel u tifla li ngħataw tliet dożi ta' Synflorix u doża booster, kien hemm każ wieħed fost l-10,000 tifel u tifla li ngħataw żewġ dożi ta' Synflorix u doża booster u dehru 12-il każ f'10,000 tifel u tifla li ngħataw il-vaċċin komparatur.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Synflorix on 30 March 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Synflorix fit-30 ta' Marzu 2009.
English: Synflorix is a vaccine that protects against infections caused by S. pneumoniae.
Maltese: Synflorix huwa vaċċin li jipproteġi kontra l-infezzjonijiet ikkawżati mill-S. pneumoniae.
English: The most common side effects with Synflorix (which may affect more than 1 in 10 people) are pain, redness and swelling at the injection site, fever, drowsiness, irritability and loss of appetite.
Maltese: L-effetti sekondarji l-aktar komuni b'Synflorix (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma wġigħ, ħmura u nefħa fis-sit tal-injezzjoni, deni, ngħas, irritabilità u nuqqas ta' aptit.
English: Synflorix contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule' that surrounds the S. pneumoniae bacterium.
Maltese: Synflorix fih ammonti żgħar ta' polisakkaridi (tip ta' zokkor) estratti mill-'kapsula' li ddawwar il-batterju S. pneumoniae.
English: What are the risks associated with Synflorix?
Maltese: X'inhuma r-riskji assoċjati ma' Synflorix?
English: The ability of Synflorix to trigger the production of antibodies (immunogenicity) was assessed in one main study involving 1,650 healthy infants aged between 6 and 12 weeks.
Maltese: Il-kapaċità ta' Synflorix li jqanqal il-produzzjoni ta' antikorpi (immunoġeniċità) ġiet evalwata fi studju prinċipali wieħed li kien jinvolvi 1,650 tifel u tifla żgħar ħafna b'saħħithom ta' bejn sitt ġimgħat u 12-il ġimgħa.
English: Based on a comparison of the immune response of Synflorix with the investigational vaccine used in the study, Synflorix is expected to provide similar protection against acute otitis media caused by S. pneumoniae.
Maltese: Abbażi ta' tqabbil tar-rispons immunitarju ta' Synflorix mal-vaċċin investigattiv użat flistudju, huwa mistenni li Synflorix għandu jipprovdi protezzjoni simili kontra l-otite medja akuta kkawżata mill-S. pneumoniae.
English: In Europe, it is estimated that these are responsible for 56 to 90% of the cases of invasive disease caused by S. pneumoniae in children under the age of 5 years.
Maltese: Fl-Ewropa huwa stmat li dawn huma responsabbli għal 56 sa 90% tal-każijiet ta' mard invażiv ikkawżat mill-S. pneumoniae fit-tfal taħt il-ħames snin.
English: Synflorix was evaluated in a large study involving over 30,000 infants below 7 months of age who were given either Synflorix or a comparator vaccine which was not active against S. pneumoniae.
Maltese: Synflorix ġie evalwat fi studju kbir li kien jinvolvi aktar minn 30,000 tifel u tifla żgħar ħafna ta' inqas minn 7 xhur li ngħataw jew Synflorix jew vaċċin komparatur li ma kienx attiv kontra l-S. pneumoniae.
English: For the full list of side effects with Synflorix, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Synflorix, ara l-fuljett ta' tagħrif.
English: The studies showed that Synflorix led to an increase in antibody production following booster vaccinations.
Maltese: L-istudji wrew li Synflorix wasslu għal żieda ta' produzzjoni fl-antikorpi wara tilqim booster.
English: However, children aged under 6 months with conditions that make them more likely to catch these invasive diseases, such as those with human immunodeficiency virus (HIV) infection, sickle cell disease or spleen problems, should be given three doses followed by a booster dose.
Maltese: Madankollu, it-tfal ta' età inqas minn sitt xhur b'kundizzjonijiet li jagħmluhom aktar vulnerabbli għall-mard invażiv, bħal dawk infettati bil-virus tal-immunodefiċjenza umana (HIV), il-marda "sickle cell" jew problemi tal-milsa, għandhom jingħataw tliet dożi segwiti minn doża booster.
English: Other information about Synflorix
Maltese: Kif jintuża Synflorix?
English: It is used to protect infants and children aged between 6 weeks and 5 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae.
Maltese: Dan jintuża sabiex jipproteġi lit-tfal żgħar u lit-tfal ta' bejn sitt ġimgħat u ħames snin kontra l-mard invażiv, il-pulmonite (l-infezzjoni fil-pulmun) u l-otite medja akuta (L-infezzjoni filwidna minn ġewwa) kkawżata mill-S. pneumoniae.
English: The majority of these reactions were of mild to moderate severity and were not long lasting.
Maltese: Ilmaġġoranza ta' dawn ir-reazzjonijiet kienu ta' severità ħafifa sa moderata u ma damux wisq.
English: Synflorix was also investigated in a large study involving around 24,000 children aged between 6 and 16 weeks that focussed mainly on the vaccine's benefit in preventing community acquired pneumonia.
Maltese: Synflorix ġie investigat ukoll fi studju kbir li kien jinvolvi madwar 24,000 tifel u tifla ta' bejn 6 ġimgħat u 16-il ġimgħa li ffoka prinċipalment fuq il-benefiċċju tal-vaċċin fil-prevenzjoni tal-pulmonite li tittieħed mill-komunità.
English: The study involved almost 5,000 infants aged 3 months and compared an investigational vaccine that contains the same polysaccharides as Synflorix with another vaccine that is not active against S. pneumoniae (in this case, a vaccine against hepatitis A virus).
Maltese: L-istudju involva madwar 5,000 tifel u tifla żgħar ħafna ta' tliet xhur u qabbel vaċċin investigattiv li kien fih listess polisakkaridi bħal Synflorix ma' vaċċin ieħor li mhuwiex attiv kontra l-S. pneumoniae (f'dan ilkaż, vaċċin kontra l-virus tal-epatite A).
English: • Premature babies (born between 27 and 36 weeks gestation) are given a course of three doses with an interval of at least one month between each dose, with the first dose given at 2 months of age.
Maltese: • It-trabi mwielda qabel iż-żmien (imwielda bejn 27 u 36 ġimgħa tqala) jingħataw tliet dożi b'intervall ta' mill-inqas xahar bejn kull doża, l-ewwel doża tingħata fl-età ta' xahrejn.
English: • When Synflorix is given as part of a routine infant immunisation programme (when all infants in an area are vaccinated at around the same time), a course of two doses may be given 2 months apart, from the age of 6 weeks, followed by a booster dose at least 6 months later.
Maltese: • Meta Synflorix jingħata bħala parti minn programm ta' immunizzazzjoni infantili ta' rutina (meta ttrabi kollha f'żona jitlaqqmu fl-istess żmien), jistgħu jingħataw żewġ dożi mogħtija xahrejn żmien minn xulxin, mill-età ta' sitt ġimgħat, segwiti minn doża booster mill-anqas sitt xhur wara.
English: A fourth (‘booster') dose is recommended at least 6 months after the third dose, preferably when the child is between 12 and 15 months of age.
Maltese: Ir-raba' doża ("booster") hija rrakkomandata minn tal-inqas sitt xhur wara t-tielet doża, preferibbilment meta t-tifel jew it-tifla jkollhom bejn 12 u 15-il xahar.
English: Invasive disease results from the bacterium spreading through the body causing serious infections such as septicaemia (blood infection), meningitis (infection of the membranes around the brain and spine) and pneumonia.
Maltese: Il-mard invażiv iseħħ meta l-batterju jinfirex malġisem kollu, u jikkawża infezzjonijiet serji bħas-settiċemija (l-infezzjoni fid-demm) u l-meninġite (linfezzjoni fil-membrani madwar il-moħħ u l-ispina) u l-pulmonite.
English: In studies in infants and older children, although Synflorix produced a lower antibody response than the comparator vaccine, it fulfilled pre-defined criteria and was considered acceptable in this group.
Maltese: L-istudji fit-trabi u fi tfal akbar urew li għalkemm Synflorix ipproduċa rispons aktar baxx ta' antikorpi mill-vaċċin komparatur, dan xorta issodisfa l-kriterji predefiniti u tqies aċċettabbli f'dan ilgrupp.
English: When a person is given the vaccine, the immune system recognises the parts of the bacterium in the vaccine as ‘foreign' and makes antibodies against them.
Maltese: Meta persuna tingħata l-vaċċin, is-sistema immunitarja tagħraf il-partijiet tal-batterju filvaċċin bħala “barranin” u tipproduċi antikorpi kontrihom.
English: The children were followed up until the end of their second year of life.
Maltese: It-tfal baqgħu jiġu ssorveljati sa tmiem it-tieni sena tagħhom.
English: The occurrence of the first episode of acute otitis media caused by S. pneumoniae was approximately halved among children who were given the investigational vaccine compared with those given the comparator.
Maltese: L-okkorrenza tal-ewwel episodju tal-otite media akuta kkawżata minn S. pneumoniae tnaqqset kważi bin-nofs fost it-tfal li ngħataw il-vaċċin investigattiv meta mqabbla ma' dawk li ngħataw il-vaċċin komparatur.
English: Tolerance
Maltese: Tolleranza
English: 2 Intrarea Vagonetului, Bl.
Maltese: 2 Intrarea Vagonetului, Bl. 101, Ap.
English: Czech Republic MIKROP ČEBÍN a.s. Čebín 416
Maltese: MIKROP ČEBÍN a.s. Čebín 416
English: Acta Agric. Scand.
Maltese: Acta Agric.
English: 101, Ap. 47 sector 6, Bucharest Romania
Maltese: 47 sector 6, Bucharest Romania
English: ScanVet Animal Health A/S Kongevejen 66
Maltese: Id-Danimarka ScanVet Animal Health A/S Kongevejen 66
English: 43206 Reus (Tarragona) Spain
Maltese: 43206 Reus (Tarragona)
English: 1998 - link
Maltese: FEDNA. 1998 - link
English: 664 23 Čebín
Maltese: 664 23 Čebín Czech Republic
English: Pre-Assessment of Environmental Impact of Zinc and Copper Used in Animal
Maltese: Pre-Assessment of Environmental Impact of Zinc and Copper Used in Animal Nutrition.
English: Discussion of data available
Maltese: Diskussjoni dwar id-data disponibbli
English: Višňová 2/484
Maltese: s r.o. Višňová 2/484
English: Vetoquinol Biowet Sp. z o. o. ul.
Maltese: Vetoquinol Biowet Sp. z o. o.
English: Andrés Pintaluba, S.A. Pol. Ind. Agro-Reus C/ Prudenci Bertrana 5 43206 Reus (Tarragona) Spain
Maltese: Andrés Pintaluba, S.A. Pol. Ind. Agro-Reus C/ Prudenci Bertrana 5 43206 Reus (Tarragona)
English: 27 Holm, A. (1990) E. coli associated diarrhoea in weaner pigs: zink oxide added to the feed as a preventive measure.
Maltese: (1990) E. coli associated diarrhoea in weaner pigs: zink oxide added to the feed as a preventive measure.
English: Hollis G. Use of Growth Promotants in Swine Feeding Programs.
Maltese: Use of Growth Promotants in Swine Feeding Programs.
English: Videnskabelig rapport fra DCENationalt Center for Miljø og Energi - nr. 159.
Maltese: Belysning af kobber- og zinkindholdet I jord. Videnskabelig rapport fra DCENationalt Center for Miljø og Energi - nr. 159. - link speċi akkwatiċi.
English: United Kingdom SCA NuTec (Provimi Ltd) Eastern Avenue
Maltese: SCA NuTec (Provimi Ltd) Eastern Avenue Lichfield
English: Czech Republic Trouw Nutrition Biofaktory s.r.o.
Maltese: Trouw Nutrition Biofaktory s.r.o.
English: DK-3480 Fredensborg Denmark
Maltese: DK-3480 Fredensborg
English: The broader context of antibiotic resistance: Zinc feed supplementation of piglets increases the proportion of multi-resistant Escherichia coli in vivo.
Maltese: Zinc feed supplementation of piglets increases the proportion of multi-resistant Escherichia coli in vivo.
English: WS13 7SE
Maltese: Staffordshire WS13 7SE
English: Czech Republic Tekro, spol.
Maltese: Tekro, spol.
English: DSM Nutritional Products (UK) Ltd. and Provimi Ltd.
Maltese: DSM Nutritional Products (UK) Ltd.
English: Zinc oxide Colistin sulfate
Maltese: Colistin sulfate
English: Dunavet-B Zrt.
Maltese: Dunavet-B
English: 26 Bednorz C, Oelgeschläger K, Kinnemann B, Hartmann S, Neumann K, Pieper R, Bethe A, Semmler T, Tedin K, Schierack
Maltese: Zoonosis and Public Health 62(4): 301-308. 26 Bednorz C, Oelgeschläger K, Kinnemann B, Hartmann S, Neumann K, Pieper R, Bethe A, Semmler T, Tedin K, Schierack
English: S.C. CRIDA PHARM S.R.L.
Maltese: S.C. CRIDA PHARM
English: Slovak Republic Andrés Pintaluba, S.A. Pol. Ind. Agro-Reus
Maltese: Is-Slovakkja Andrés Pintaluba, S.A. Pol. Ind.
English: D-48308 Senden-Bösensell Germany aniMedica Enteroxid N Zinc oxide Colistin sulfate
Maltese: D-48308 Senden-Bösensell Germany aniMedica Enteroxid N
English: s r.o., Vepidan Aps, Vetlima S.A., Vetoquinol Biowet Sp. z o. o. and Vetpharma Animal Health S.L.
Maltese: s r.o., Vepidan Aps, Vetlima S.A., Vetoquinol Biowet Sp. z o. o.
English: 4 Hu CH, Xiao K, Song J, Luan ZS.
Maltese: Hu CH, Xiao K, Song J, Luan ZS. 2013b.
English: Horní Počernice
Maltese: Horní Počernice Czech Republic
English: Trckova M, Lorencova A, Hazova K, Sramkova Zajacova Z. 2015.
Maltese: K, Sramkova Zajacova Z. 2015.
English: Chapter R.7b:Endpoint specific guidance 16 VICH GL6: Guideline on Environmental Impact Assessment (EIAS) for Veterinary Medicinal Products - Phase I
Maltese: 17 VICH GL38: Guideline on Environmental Impact Assessment for Veterinary Medicinal Products Phase II
English: The Netherlands Huvepharma NV Uitbreidingstraat 80
Maltese: In-Netherlands Huvepharma NV Uitbreidingstraat 80
English: This restricts the focus to the findings of Poulsen (1995), and Holm (1990)27.
Maltese: Dan jillimita lfokus għas-sejbiet ta' Poulsen (1995) u Holm (1990)27.
English: In sandy soils, PNECs were exceeded in 66% of all cases.
Maltese: F'ħamrija ramlija, il-PNECs inqabżu f'66 % tal-każijiet kollha.
English: In order to better indicate the risks posed at application rates considered particularly relevant by the use of Gutal of 8.2 kg zinc ha-1 y-1, 7.2 kg zinc ha-1 a-1, 3.3 kg zinc ha-1 a-1 and 2.8 kg zinc ha-1 a-1, RQs have been extrapolated (linearly) from application rates of 4 and 7 kg zinc ha-1 a-1.
Maltese: Sabiex jiġu indikati aħjar ir-riskji maħluqin fir-rati ta' applikazzjoni kkunsidrati partikolarment rilevanti bl-użu ta' Gutal ta' 8.2 kg żingu ha-1 y-1, 7.2 kg żingu ha-1 a-1, 3.3 kg żingu ha-1 a-1 u 2.8 kg żingu ha-1 a-1, l-RQs ġew estrapolati (b'mod lineari) mir-rati ta' applikazzjoni ta' 4 u 7 kg żingu ha-1 a-1..
English: Zinc oxide Sulfaguanidin um
Maltese: Sulfaguanidin um
English: Colistin alone is sufficiently effective for the metaphylaxis and treatment of gastrointestinal infections caused by non-invasive E. coli (see procedure EMEA/V/A/106)10.
Maltese: Colistin waħdu hu effettiv biżżejjed għall-metafilassi u l-kura ta' infezzjonijiet gastrointestinali kkawżati minn E. coli mhux invażiva (ara l-proċedura EMEA/V/A/106)10.
English: Following the CVMP opinion of 8 December 2016 on this referral procedure, several marketing authorisation holders (aniMedica GmbH, Huvepharma N.V., DSM Nutritional Products (UK) Ltd., Provimi Ltd., Andrés Pintaluba S.A., Bio Vet Aps, Calier Portugal S.A., Dunavet-B Zrt., Industrial Veterinaria S.A., Laboratorios Calier S.A., Laboratorios Support Pharma S.L., S.C. Crida Pharm S.R.L., ScanVet Animal Health A/S, Sintofarm S.p.A, Tekro, spol.
Maltese: ' riferiment, diversi detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq (aniMedica GmbH, Huvepharma N.V., DSM Nutritional Products (UK) Ltd., Provimi Ltd., Andrés Pintaluba S.A., Bio Vet Aps, Calier Portugal S.A., Dunavet-B Zrt., Industrial Veterinaria S.A., Laboratorios Calier S.A., Laboratorios Support Pharma S.L., S.C.Crida Pharm S.R.L., ScanVet Animal Health A/S, Sintofarm S.p.A, Tekro, spol.
English: VICH GL38: Guideline on Environmental Impact Assessment for Veterinary Medicinal Products Phase II (CVMP/VICH/790/03) - link
Maltese: Guideline on Environmental Impact Assessment (EIAS) for Veterinary Medicinal Products - Phase I (CVMP/VICH/592/98) - link
English: The published data from Hu et al. (Hu et al., 2013a3; Hu et al., 2013b4) showed in two different nonGCP studies a statistically significant effect on faecal consistency (scored from 1 to 5) of the feed supplementation with 2250 ppm zinc in weaned piglets (aged 21 days) for 14 days, in comparison with a negative control.
Maltese: (Hu et al., 2013a3; Hu et al., 2013b4), f'żewġ studji differenti mhux PKT, uriet effett statistikament sinfikanti ta' konsistenza tal-ippurgar (li kellu punteġġ ta' minn 1 sa 5) tas-supplimentazzjoni tal-għalf b'2250 ppm żingu fi qżieqeż miftuma (li kellhom 21 jum) għal 14il jum, meta mqabbel ma' kontroll negattiv.
English: Report to the European Food Safety Authority - link 20 EFSA Scientific Opinion on safety and efficacy of zinc compounds (E6) as feed additive for all animal species: Zinc oxide, based on a dossier submitted by Grillo Zinkoxid GmbH/EMFEMA - link validation of the IDMM has been performed by the comparison of model predictions against published monitoring data for zinc applications.
Maltese: Report to the European Food Safety Authority - link 20 EFSA Scientific Opinion on safety and efficacy of zinc compounds (E6) as feed additive for all animal species:
English: Zinc oxide Sulfaguanidin e
Maltese: Sulfaguanidin e
English: In 45% of all soil samples, PNECs were already exceeded.
Maltese: F'45 % tal-kampjuni kollha talħamrija, il-PNECs diġà kienu nqabżu.
English: Vilofarm A/S Søagervej 9, Sdr. Onsild DK-9500 Hobro Denmark
Maltese: Onsild DK-9500 Hobro
English: The exposure assessment should ideally have addressed this and considered a realistic worst-case situation with respect to the respective receiving environmental compartments.
Maltese: Il-valutazzjoni tal-esponiment għandha idealment tindirizza dan u tikkunsidra l-agħar sitwazzjoni possibbli realistika fir-rigward tal-kompartimenti ambjentali riċevuti rispettivi.
English: Oral powder
Maltese: Trab orali
English: Enteroxid N AMV aniMedica
Maltese: AMV aniMedica
English: No clinical data was identified to support the claimed indication ‘prevention and treatment of various types of diarrhoea occurring at the weaning'.
Maltese: Ma ġiet identifikata l-ebda data klinika biex tappoġġja l-indikazzjoni li saret “prevenzjoni u kura ta' diversi tipi ta' dijarea li jseħħu waqt il-ftim”.
English: Huvepharma NV Uitbreidingstraat 80 2600 Antwerpen Belgium
Maltese: Huvepharma NV Uitbreidingstraat 80 2600
English: 1 CVMP opinion on Article 33(4) referral for Gutal 1000 g/kg premix for medicated feeding stuff for piglets (Procedure no. EMEA/V/A/108) - link results was submitted and study methods were poorly reported (no study protocols, no raw data, no statistical analysis).
Maltese: 1 CVMP opinion on Article 33(4) referral for Gutal 1000 g/kg premix for medicated feeding stuff for piglets (Procedure no.
English: The CVMP considers that because Enteroxid products are included within the scope of this procedure under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing zinc oxide to be administered orally to food producing species, such argument is not applicable.
Maltese: 10 CVMP procedure under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing colistin as a sole active substance to be administered orally (Procedure no.
English: 23 CVMP reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products (EMA/CVMP/ERAWP/409328/2010) - link treated manure to different areas of land, but also because of the trade on manure between Member States and possibility for manure containing high concentrations of zinc oxide being used in susceptible soil types.
Maltese: 23 CVMP reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products (EMA/CVMP/ERAWP/409328/2010) - link importanza ta' dawn is-sejbiet għas-saħħa tal-annimali u tal-pubbliku tibqa
English: Pulvis for oral use
Maltese: Pulvis għal użu orali
English: United Kingdom Huvepharma NV Uitbreidingstraat 80
Maltese: Id-Danimarka Huvepharma NV Uitbreidingstraat 80
English: Based on the data on Gutal, to assess the risk for each compartment following extended application of manure to land, PECs and PNEC values for each FOCUS21 scenario were compared at three time points (years: 2020, 2040, 2060), using two application rates: application rate of 7 kg zinc ha-1 a-1 and a lower application rate of 4 kg zinc ha-1 a-1.
Maltese: Abbażi tad-data dwar Gutal, biex jiġi vvalutat ir-riskju għal kull kompartiment wara applikazzjoni estiża ta' demel lill-art, il-valuri PECs u PNEC għal kull xenarju FOCUS21 tqabblu fi tliet punti ta' żmien (snin: 2020, 2040, 2060), bl-użu ta' żewġ rati ta' applikazzjoni: rata ta' applikazzjoni ta' 7 kg żingu ha-1 a-1 u rata ta' applikazzjoni aktar baxxa ta' 4 kg żingu ha-1 a-1.
English: Zinc oxide 622mg/g (500 mg zinc/g)
Maltese: 622mg/g (500 mg zinc/g)
English: Zinc oxide as a sole active substance
Maltese: Ossidu taż-żingu bħala sustanza attiva unika
English: 21 Forum for Co-ordination of Pesticide Fate Models and their Use (FOCUS) - link
Maltese: Zinc oxide, based on a dossier submitted by Grillo Zinkoxid GmbH/EMFEMA - link 21 Forum for Co-ordination of Pesticide Fate Models and their Use (FOCUS) - link
English: At higher dose (x3 during 28 days) significant side effects (impact on growth rate, clinical signs) have been observed.
Maltese: B'doża ogħla (x3 matul 28 jum), ġew osservati effetti sekondarji sinifikanti (impatt fuq ir-rata ta' tkabbir, sinjali kliniċi).
English: Zinc oxide 622 mg/g (500 mg zinc/g)
Maltese: 622 mg/g (500 mg zinc/g)
English: It is believed that bioavailability of metals in sediment can be predicted by measuring the acid volatile sulphide (AVS) and the simultaneously extracted metal (SEM) contents of sediments.
Maltese: Huwa maħsub li l-bijodisponibbiltà tal-metalli fis-sediment tista' tiġi prevista billi jitkejjel is-sulfur volatili tal-aċidu (AVS, acid volatile sulphide) u l-kontenuti ta' metall estratt simultanjament (SEM, simultaneously extracted metal) tas-sedimenti.
English: The study was performed on 260 piglets from 36 litters weaned at the age of 28 days and assigned, according to initial body weight and the litter of origin, to one of six treatment groups: 0 ppm zinc, 100 ppm zinc; 200 ppm zinc; 1000 ppm zinc; 2500 ppm zinc and 4000 ppm zinc.
Maltese: L-istudju sar f'260 qażquż minn 36 grupp miftuma fl-età ta' 28 jum u ġew assenjati skont l-piż tal-ġisem inizjali u l-grupp ta' oriġini, għal wieħed minn sitt gruppi ta' kura: 0 ppm żingu, 100 ppm żingu; 200 ppm żingu; 1000 ppm żingu;
English: In the absence of relevant diagnostic data it was not possible to identify the pathogens involved.
Maltese: Finnuqqas ta' data dijanjostika rilevanti ma kienx possibbli li jiġu identifikati l-patoġeni involuti.
English: Cloning and occurrence of czrC, a gene conferring cadmium and zinc resistance in Methicillin-Resistant Staphylococcus aureus CC398 isolates.
Maltese: Cavaco LM, Hasman H, Stegger M, Andersen PS, Skov R, Fluit AC, Ito T, Aarestrup FM. 2010. Cloning and occurrence of czrC, a gene conferring cadmium and zinc resistance in Methicillin-Resistant Staphylococcus aureus CC398 isolates.
English: A study to evaluate the effects of adding high amounts of zinc in the diets of weaned pigs (Lima et al., 1994)9 included 162 piglets from a farm with a previous history of diarrhoea due to E. coli.
Maltese: Studju biex jiġu vvalutati l-effetti taż-żieda ta' ammonti għoljin ta' żingu fid-dieti ta' ħnieżer miftuma (Lima et al., 1994)9 inkluda 162 qażquż minn razzett bi storja preċedenti ta' dijarea minħabba E. coli.